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Eight adult patients (ages 18–58, 5 women) with Buruli 
ulcer (BU) conﬁ  rmed by at least 2 diagnostic methods were 
seen in a 10-year period. Attempts to culture Mycobacterium 
ulcerans failed. Five patients came from jungle areas, and 3 
from the swampy northern coast of Peru. The patients had 
1–5 lesions, most of which were on the lower extremities. 
One patient had 5 clustered gluteal lesions; another patient 
had 2 lesions on a ﬁ  nger. Three patients were lost to follow-
up. All 5 remaining patients had moderate disease. Diverse 
treatments (antituberculous drugs, World Health Organiza-
tion [WHO] recommended antimicrobial drug treatment for 
BU, and for 3 patients, excision surgery) were successful. 
Only 1 patient (patient 7) received the speciﬁ  c drug treat-
ment recommended by WHO. BU is endemic in Peru, al-
though apparently infrequent. Education of populations and 
training of health workers are ﬁ  rst needed to evaluate and 
understand the full extent of BU in Peru.
B
uruli ulcer (BU), a chronic ulcerative disease, has been 
observed in many tropical areas, but patients have 
usually come from Africa and Australia (1–6). Cases were 
also described in the Americas, mostly in French Guiana 
(3,6). A few cases from Surinam have also been recorded in 
French Guiana, and 8 cases have been reported in Mexico 
since 1953 (3,6).
In 1969, the ﬁ  rst 2 cases from Peru were reported (7). 
A new case was reported in 1988, along with a redescrip-
tion of the ﬁ  rst 2 cases (8). From 1996 through 2005, 8 
additional cases, which we describe here, were found in 
Peru (Figure 1).
Material and Methods
We conducted a descriptive, retrospective survey of 
patients seen by members of the Instituto de Medicina 
Tropical Alexander von Humboldt in Lima and Iquitos. We 
requested referrals of new patients from other areas. The 
total of 8 cases occurred from 1996 through 2005.
Patients
We used a collective data sheet proposed by the World 
Health Organization (WHO) (9) to assess the magnitude and 
severity of the disease and to collect data from patients. We 
also obtained information from medical records. Patients 
who had a history of chronic ulcer and who had at least 2 
different positive laboratory tests were included in this study 
(10). All the patients gave consent verbally. The publication 
was approved by the Human Protections Administration Of-
ﬁ  ce for Human Research Protection of the Universidad Pe-
ruana Cayetano Heredia (SIDISI code 52467).
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Figure 1. Map of Peru showing the locations where 8 Buruli ulcer 
patients were probably infected. Red, Peruvian River basin; gold, 
coastal area.RESEARCH
Smears and Tissue Collection
Smears obtained by scalpel or swab were prepared 
with material from the necrotic base and undermined edges 
of the lesions and were stained with Ziehl-Neelsen. Skin 
biopsy samples were excised and cut into >2 portions. At 
least 1 portion was ﬁ  xed in 10% formalin and processed 
for histologic examination at the pathology laboratory of 
the Hospital Nacional Cayetano Heredia in Lima. The other 
portions, minced further, were inoculated after decontami-
nation onto Löwenstein-Jensen medium in Lima as de-
scribed previously (10); the rest was placed in a semisolid 
transport medium (11) and sent to the Institute of Tropical 
Medicine, Antwerp, for culture and PCR testing (10).
Results
We found 8 cases of BU from 1996 to 2006. Case char-
acteristics are indicated in Table 1. Five patients came from 
the Peruvian rainforest, the likely place of infection. Two 
patients reported close contact with water in the Marañón 
(patient 1) and Huallaga (patient 2) River basins. Three pa-
tients (patients 3, 4, and 6) lived close to Iquitos, a city on 
the Amazon River. One patient (patient 5) had brieﬂ  y visit-
ed a swampy area in the north coast of Peru (Tumbes), and 
2 other patients (patients 7 and 8) lived in the same area. All 
of the areas described are warm and humid. The age range 
at diagnosis was 18–58 years, with a male to female ratio of 
3:5. No case patients had a medical or family history of tu-
berculosis or leprosy. The time between onset of illness and 
being seen by a physician was 1–8 months. Four patients 
noticed a nodular lesion before ulceration occurred. All pa-
tients had ulcers with typical undermined edges. The site 
of involvement in our patients was on the extremities, but 
1 patient had gluteal lesions. The median number of lesions 
per patient was 2. Three patients (patients 1, 2, and 5) were 
lost to follow-up at an early stage, soon after diagnosis, and 
their disease course was unknown. 
Patient 3 had lesions on both knees; he liked gardening 
and often knelt on soil and organic mulch that contained 
wood shavings. He ﬁ  rst received rifampin and ethambutol 
for 5 weeks. Drug therapy was stopped because of hepato-
toxicity. Trimethoprim-sulfamethoxazole and ciproﬂ  oxacin 
were then administered for 15 days. After completing oral 
therapy, he treated his lesions with a rifampin spray. Eight 
months after the start of drug therapy, the lesions were al-
most closed. A small ulcer remained on the right knee. The 
patient showed complete remission of lesions without any 
surgical intervention on his last control visits, 3 and 5 years 
after diagnosis. 
Patient 4 had a medical history suggestive of leishman-
iasis, and a smear from an ulcerated lesion was reported as 
positive for Leishmania. She was treated with intramuscu-
lar and intralesional sodium stibogluconate, including mul-
tiple inoculation sites. One month after receiving a course 
of 29 intramuscular injections, she showed more lesions in 
the left gluteal region and was treated with herbal medicine. 
BU was diagnosed from purulent material removed with a 
syringe and needle from a closed lesion. After drainage and 
biopsy her lesions showed improvement, and therefore no 
other treatment was instituted. She continued herbal treat-
ment until total cure. The lesions have remained inactive 
for 5 years. 
Patient 6 was treated by excision surgery and later re-
ceived antituberculosis treatment (regimen 1) for 6 months. 
Patient 7 was pregnant when ﬁ  rst seen. After tissue speci-
mens were taken and BU was diagnosed, she was treated 
conservatively with topical disinfectants until delivery. She 
then received the WHO-recommended rifampin and strep-
tomycin treatment (12) for 31 days and had excision sur-
gery of the largest lesions. Later, all lesions were excised. 
Patient 8 had lesions on the right middle ﬁ  nger (Figure 2, 
panel A) that ulcerated after treatment for 1 month with 
ciproﬂ  oxacin, clindamycin, and dexametasone (Figure 2, 
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Table 1. Case descriptions of Buruli ulcer, Peru* 
Patient
no.
Geographic 
origin Age, y/sex
Patient
delay, mo
Localized
pain No. of lesions Sites
Size of main 
lesion, cm Treatment
1 Marañón 18/M 8 Positive 2 Left knee 7 × 6 Lost to follow-up, no 
treatment
2 Huallaga 22/F 1 Positive 1 Left thigh 2 × 3 Lost to follow-up, no 
treatment
3 Iquitos 54/M 2 Positive 2 (right knee 
earlier, larger)
Both knees 6 × 7 Antituberculous drugs 
and herbal medicines
4 Iquitos 58/F 8 Positive 5 (in a single 
group)
Left gluteal 
region
12 × 16 
(sum of all 5)
Anti-Leishmania and 
herbal medicines
5 Tumbes 46/F 8 Positive 2 (1 lesion was 
a scar)
Left foot 5 × 6 Lost to follow-up, no 
treatment
6 Iquitos 21/F 3 Positive 1 Right thigh 5 × 5 Antituberculous drugs 
(regimen 1) and surgery
7 Tumbes 34/F 2 Positive 4 Right thigh 
and leg
6 × 8 WHO BU antibiotics and 
surgery
8 Tumbes 45/M 1 Positive 2 Right middle 
finger
8 × 2 Antituberculous drugs 
(regimen 1) and surgery
*WHO, World Health Organization; BU, Buruli ulcer. Mycobacterium ulcerans Disease, Peru
panel B). Diagnosis was made on the basis of material ob-
tained at the ﬁ  rst extensive debridement (Figure 2, panel 
C). He received 5 weeks of regimen 1 treatment for tu-
berculosis, to which streptomycin was added for the last 
3 weeks before surgical debridement and autologous skin 
graft. Antituberculous regimen 1 was continued for 2 more 
weeks. Figure 2, panel D shows the lesion 1 month after 
surgery. The patient then received 4 months of treatment 
with minocycline, ciproﬂ  oxacin, and trimethoprim-sulfa-
methoxazole and undertook rehabilitation including exer-
cises. He recovered very good use of his right hand. 
Patients 6, 7, and 8 were cured with antimicrobial 
agents and surgery. They had no recurrence after 2 years 
of follow-up.
As indicated in Table 2, all patients’ cases were con-
ﬁ  rmed by at least 2 positive laboratory tests. Seven patients 
showed acid-fast bacilli (AFB) on the initial smear, and 1 
was negative (patient 5). The biopsy specimens from all 
the patients had AFB in histopathologic sections and typi-
cal histologic lesions, i.e., necrosis of fat and an abundance 
of extracellular clumps of AFB. Most biopsy specimens 
showed little or no inﬂ  ammatory inﬁ  ltrate. A granuloma-
tous inﬁ  ltrate was seen in the biopsy specimen from patient 
5. Cultures remained negative, and IS2404 PCR was posi-
tive for all 7 patients tested.
Discussion
From 1969 until 2007, only 11 cases of BU have been 
reported in Peru, but no countrywide survey has been con-
ducted to evaluate its true prevalence in Peru. BU is probably 
both infrequent and underreported in Peru and may often be 
misdiagnosed as leishmaniasis, which is more prevalent and 
better known. Three separate surveys suggest the rarity of 
BU. In the ﬁ  rst, Saldaña-Patiño reviewed 1,620 ulcers bi-
opsied from 1969 to 1981 and found no other BU patients 
apart from the 3 he reported (8). Second, a preliminary epi-
demiologic survey was conducted in the general area of the 
Huallaga Basin close to Tarapoto; several leishmaniasis and 
vascular lesions were found in 4 communities of ≈4,000 
inhabitants, but no BU cases were seen (N. Donaires, MD 
thesis). Finally, physicians performing populationwide cys-
ticercosis research in Tumbes (on the north coast) included 
a questionnaire and physical examination of all skin ulcers 
at the time, using as a guide a booklet in Spanish that was 
provided to familiarize them with BU (13). No skin ulcers 
were seen in the population surveyed.
The scarcity of BU cases in Peru and Mexico may be 
due to a lower virulence of the mycobacteria and a better im-
mune response of patients when they become infected by M. 
ulcerans. It is clearly not related to infrequent contact with 
contaminated water. As in Africa, populations living in the 
Amazon River Basin have frequent contacts with water for 
domestic activities. Similarly, the low incidence of BU in 
Peru does not seem to be related to the absence of M. ul-
cerans in the environment, since the IS2404 PCR positiv-
ity of the environmental specimens from Peru (collected in 
Tarapoto, in the Huallaga River Basin) and Benin have given 
comparable results (14% positivity in Peru vs. 10%–20% 
positivity in Benin) (F. Portaels et al., unpub. data).
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Figure 2. Patient 8. A) Nonulcerative edematous lesion on the right 
middle ﬁ  nger as ﬁ  rst seen; B) ulcerated lesions on the right middle 
ﬁ  nger ≈4 weeks later; C) extensive debridement, 5.5 weeks after 
ﬁ  rst seen; D) cured lesion 5 months after ﬁ  rst seen, 1 month after 
autologous skin graft.
Table 2. Diagnostic laboratory studies on patients with Buruli ulcer, Peru* 
Patient
no. ITM no. AFB in smear (ZN) Histopathologic changes
AFB in histologic 
sections IS2404 PCR Culture
1 None Positive Necrosis of fat Positive ND ND
2 96–0729 Positive Necrosis of fat Positive Positive Contaminated
3 01–0720 Positive Necrosis of fat Positive Positive Negative
4 02–1536 Positive Necrosis of fat Positive Positive Contaminated
5 02–1877 Negative (only 1 
AFB seen)
Necrosis of fat + 
granulomatous infiltrate
Positive Positive Negative
6 04–0872 Positive Necrosis of fat Positive Positive Negative
7 05–2249
05–2411
Positive Necrosis of fat + inflammation Positive Positive Negative
8 None Positive Necrosis of fat + inflammation Positive Positive Negative
*ITM, Institute of Tropical Medicine; AFB, acid-fast bacilli; ZN, Ziehl-Neelsen staining; ND, not done. RESEARCH
The distribution of BU in Peru and elsewhere is 
strongly associated with wetlands, especially those with 
slow-ﬂ  owing or stagnant water (e.g., ponds, backwaters, 
and swamps) (4,5). All of our patients had contacts with 
swampy areas in the Amazon River Basin (5 patients) or on 
the northern coast (3 patients). The 3 previously reported 
patients (8) had been in contact with water bodies related 
to tributaries of the Amazon River. In Peru, therefore, BU 
is present in the Peruvian jungle (14) and other swampy 
regions of the north coast.
In our study, the age of patients when they were ﬁ  rst 
seen with BU ranged from 18 to 58 years. M. ulcerans is 
seen mainly in children and young adults in other BU-en-
demic regions but may affect any age group (4,5,15). All 
patients except patient 8 had lesions on the lower limb (Ta-
ble 1). A similar pattern has been reported in other coun-
tries (4,5,15).
Patients sought medical assistance ≈1 month after the 
ﬁ  rst lesion appeared. The longest interval to ﬁ  nal diagnosis 
was 8 months, which led to a very large lesion in patient 4, 
who was originally being treated for leishmaniasis.
In Africa, the stigma associated with BU appears to 
be important, and its mysterious nature is often attribut-
ed to witchcraft and curses (16–18). Such concerns were 
not voiced by any of our patients, as they all had actively 
sought medical help.
Beside patients lost to follow-up, the clinical outcome 
of all patients from Peru was favorable. One patient (pa-
tient 4) was cured with herbal medicine only. Several au-
thors report that while some topical treatments may heal 
BU lesions (4,19), other lesions may heal spontaneously 
(20). Patient 4 may have healed spontaneously or because 
of herbal medicine. Surgical treatment alone, which was 
until recently the mainstay of clinical management of BU 
in BU-endemic areas (4) is not practiced in Peru. Surgery 
is always associated with antimycobacterial drug therapy. 
Several centers in Africa have started to treat patients with 
streptomycin and rifampin according to WHO guidelines 
(12), and a recent study indicates that after 8 weeks of drug 
therapy ulcers may heal without surgery (21). The patients 
with reported infections in Peru up to 1988 had a favorable 
response to antituberculous therapy, although their lesions 
were large (7). In our study, patient 3 was also successfully 
treated with drug therapy without surgery. The success of 
antimycobacterial therapy in some areas may be correlated 
with a lower virulence of the M. ulcerans strains and in 
particular with lower production of mycolactones. African 
strains, which produce the greatest number and quantity 
of mycolactones, are associated with more severe disease 
forms (22), which may explain the difﬁ  culty treating some 
patients with only antimycobacterial drugs.
All patients in our study were PCR positive, but we 
were unable to cultivate M. ulcerans from the clinical 
specimens in Lima or Antwerp. This is surprising since the 
procedures used to cultivate M. ulcerans in primary culture 
were identical to those used for thousands of specimens 
from patients from other parts of the world (which yielded 
45% of positive primary cultures) (11). Peruvian M. ulcer-
ans strains may have different growth requirements or may 
be more sensitive to the antimicrobial agents in semisolid 
transport medium (PANTA: polymixin B, amphothericin 
B, nalidixic acid, trimethoprim, and azlocillin) than those 
from other geographic locations.
In conclusion, our study conﬁ  rms that, although in-
frequently diagnosed, BU is an endemic disease in tropi-
cal swampy areas of Peru. Proper diagnosis and treatment 
require inclusion of simple clinical and laboratory guide-
lines in tuberculosis, leprosy, and leishmaniasis control 
programs, which reach health workers at all levels. Known 
BU-endemic areas should receive special emphasis. Educa-
tion of populations and training of health workers are ﬁ  rst 
needed to evaluate and understand the full extent of this 
disease in Peru.
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etymologia etymologia
Mycobacterium
[mi′-ko-bak-tēr-eəm], from the Greek—myces (fungus) and baktērion (little rod)
The only genus of bacteria in the family Mycobacteriaceae. In 1882, German scientist Robert Koch reported the 
discovery of a bacillus from the lung tubercles that caused tuberculosis. Earlier, Norwegian researcher G.H.A. 
Hansen had identiﬁ  ed a similar microbe which caused leprosy. In 1896, the genus name Mycobacterium, from the 
Middle Latin noun meaning fungus rodlet, was proposed to include these new pathogens, M. tuberculosis and 
M. leprae. The name does not mean that mycobacteria are fungi; rather, the tubercle bacilli grow on the surface of 
liquid media as moldlike pellicles when cultured. The nomotile, acid-fast, aerobic organisms in this genus cause 
numerous human and animal diseases.
Source:  Sources: Savin JA, Wilkinson DS. Mycobacterial infections including tuberculosis. In: Rook A, Wilkinson DS, Ebling FJG, 
Champion RH, Burton JL, editors. Textbook of dermatology. Vol.1, 4th ed. Boston: Blackwell Scientiﬁ  c Publications; 1986. p. 791–
822. Goodfellow M, Magee JG. Taxonomy of mycobacteria. In: Mycobacteria: basic aspects. Gangadharam PRJ, Jenkins PA, 
editors. Boca Raton (FL): Chapman & Hall; 1998. p.1. Wayne LG. The “atypical” mycobacteria: recognition and disease association. 
CRC Crit Rev Microbiol. 1985;12:185–222.